Health · NYSE ARCA · USD · Data as of 2026-05-13
AUM
$2.30B
Expense ratio
0.55%
Yield
0.55%
YTD return
-0.56%
Last price
$212.70
Unclassified · Coverage 63% · low
Today
80.5
Outlook
61.5
Block A (composite-derived)
59.3
Block C (market behavior)
98.6
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
59.3
Coverage 63% · medium
Liquidity
—
Expenses
65.0
Performance
—
Volatility
—
Dividend
0.0
Concentration
55.0
Smart Money
73.4
Activist
100.0
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund from First Trust in the Mixed asset class. Launched in 2006. Assets under management: 2,303,362,304.
The fund tracks the NYSE Arca Biotechnology Index.
Bullish Whales composite rating: 59 out of 100. Evidence coverage 63% across 5 of 8 axes. Strongest axes: activist exposure, smart-money flow, expenses.
Annualized one-year realized volatility 582%, classified high. Weakest axes: dividend, concentration.
Top-10 weight 0%, diversified, led by NEO. Trailing yield 0%.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, dividend_score, expenses_score, smart_money_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, benchmark, benchmark_provider, fund_type, inception_date, issuer, name, replication_method, ticker, volatility_1yFirst Trust NYSE Arca Biotechnology Index Fund is an exchange-traded fund (ETF) that primarily tracks the performance of the NYSE Arca Biotechnology Index. Designed to provide investors exposure to the biotechnology sector, this ETF includes companies involved in the research, development, and manufacture of various therapeutics and medical treatments. Its primary function is to provide liquidity and diversification, allowing investors to gain access to a wide array of biotechnology companies through a single financial instrument. The fund comprises a basket of stocks from prominent biotechnology companies, reflecting the dynamic and innovative nature of this sector. Given the rising demand for advanced medical solutions, this ETF plays a critical role in the financial markets by enabling investors to capitalize on the growth potential within the biotech industry. Furthermore, it actively impacts sectors such as pharmaceuticals, healthcare, and life sciences. By spreading investments across a variety of companies, the fund helps mitigate individual company risk, thus appealing to investors seeking both growth opportunities and sector diversification.
Net AUM change history is not yet available for this ETF. Fund-flow time series is a Phase B deliverable.
Current AUM: $2,303,362,304. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for FBT are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.